This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Mahiuddin Ahmed, PhD
Chief Scientific Officer at Y-mAbs Therapeutics, Inc.


Mahiuddin Ahmed, PhD, is currently the CSO of Y-mAbs Therapeutics and was previously a faculty member in the Department of Pediatrics at Memorial Sloan Kettering Cancer Center. Dr. Ahmed specializes in therapeutic antibody engineering based on in silico design. He received his PhD in Biochemistry and Structural Biology from Stony Brook University and completed postdoctoral training in cancer immunotherapy at the Sloan Kettering Institute. Dr. Ahmed’s research has focused on: 1) engineering bispecific antibodies for immune cell recruitment, 2) payload delivery strategies, and 3) development of TCR-like monoclonal antibodies to target intracellular cancer antigens.